Galmed Pharmaceuticals Ltd. (GLMD)
| Market Cap | 3.70M +12.0% |
| Revenue (ttm) | n/a |
| Net Income | -11.12M |
| EPS | -2.02 |
| Shares Out | 6.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,087 |
| Open | 0.5569 |
| Previous Close | 0.5569 |
| Day's Range | 0.5300 - 0.5816 |
| 52-Week Range | 0.4111 - 1.6500 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About GLMD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated... [Read more]
Financial Performance
Financial StatementsNews
Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s
Galmed (GLMD) announced continued advancement of Aramchol as a potential disease-modifying therapy for Parkinson’s disease, or PD, reporting significant progress in development of new Aramchol orally ...
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term tre...
Galmed announces development of novel LNP cardiac targeted Aramchol formulation
Galmed (GLMD) announced the breakthrough development of a new Aramchol-based lipid nanoparticles formulation, or LNP, for targeted delivery to the heart. The development work, a collaboration between ...
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's bi...
Galmed announces restructured acquisition terms for Colospan
Galmed (GLMD) announces that following a restructuring of the acquisition terms, it consummated the acquisition of Colospan a commercial-stage medical device company that has developed a clinically di...
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.
Galmed to acquire Colospan in cash and stock deal
Galmed (GLMD) Pharmaceuticals announced that it has entered into a definitive agreement to acquire Colospan, a commercial-stage medical device company that has developed a clinically differentiated so...
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG...
Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis
Galmed (GLMD) and Tissue Dynamics announced results from a preclinical study evaluating a combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARalpha agonist. The study identified ...
Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis
Galmed (GLMD) and Tissue Dynamics announced results from a preclinical study evaluating a combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARalpha agonist. The study identified ...
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conve...
Galmed reports results from first-in-man PK study of Aramchol Meglumine
Galmed (GLMD) announced milestone results from a Phase 1 PK study in healthy subjects. The overall objective of the study was to identify the dose of Aramchol meglumine – AM…
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidifi...
Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform
Galmed (GLMD) Pharmaceuticals and Tissue Dynamics announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol...
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Is...
Galmed announces research agreement with Ramot at Tel Aviv University
Galmed (GLMD) Pharmaceuticals announced a research collaboration agreement with Ramot at Tel Aviv University to evaluate Galmed’s brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for ...
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinop...
Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?
Galmed Pharmaceuticals stock took off today alongside an update on the company’s Parkinson disease treatment, Aramchol.
Galmed announces development of brain penetrating formulation of Aramchol
Galmed (GLMD) announced the breakthrough development of a brain penetrating new formulation of Aramchol. Crossing of the blood-brain barrier, or BBB, is an essential step to achieve effective treatmen...
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode ...
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases ...
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases a...
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramcho...
Galmed granted new Use Patent related to lead compound Aramchol
Galmed (GLMD) announced the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra for…
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in th...